



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Doxifluridine-d₃

| | |
|---------------------------|---|
| Cat. No.: | HY-B0021S1 |
| Molecular Formula: | C ₉ H ₈ D ₃ FN ₂ O ₅ |
| Molecular Weight: | 249.21 |
| Target: | Thymidylate Synthase; Isotope-Labeled Compounds |
| Pathway: | Apoptosis; Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | Doxifluridine-d ₃ is deuterated labeled Doxifluridine (HY-B0021). Doxifluridine has anticancer activity. Doxifluridine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs ^{[1][2][3]} . |
| In Vitro | <p>Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].</p> <p>Doxifluridine (1-10 μM) inhibits angiogenesis by significantly inhibiting the expression of VEGF in FU-MMT-1 cells^[2].</p> <p>Doxifluridine (1-100 μM) slightly increases the expression of TSP-1 at low dose (1 μM) and inhibits the expression of TSP-1 at high dose (100 μM) in FU-MMT-1 cells^[2].</p> <p>Doxifluridine (100 μM) inhibits cell proliferation in HUVEC cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |
| In Vivo | <p>Doxifluridine (61.55 mg/kg; Intragastric administration; Single dose) has anticancer activity in BALB ? ca Jcl-nu mice, and can significantly enhance anticancer activity in combination with TNP-470 (HY-101932)^[2].</p> <p>Doxifluridine (200 mg/kg; Intraperitoneal injection; Single dose) can inhibit thymidine synthase activity in DMH-induced colon cancer mice^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |

REFERENCES

- [1]. Naganuma Y, et al. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. *Cancer Sci.* 2011 Aug;102(8):1545-52.
- [2]. Berne M, et al. Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. *Cancer Invest.* 1988;6(4):377-83.
- [3]. Di Bartolomeo M, et al. Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study. *Tumori.* 1999 May-Jun;85(3):211-3.
- [4]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA